2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Coordination Chemistry of +3 Actinium

Ottawa, ON, Canada (UroToday.com) The success of using Ac225 for radiotherapy depends on the development of chelates capable of binding the isotope strongly enough to withstand delivery to the tumor site. The basic chemistry of Ac3+ is not fully understood. Dr. Kozimor began by discussing stereo "size" effects with DOTA, a very popular chelate. Y111 is small enough to easily "fit" within the DOTA structure.

La3 is bigger but still can be contained within DOTA. Ac3 is larger still, and the binding is more complicated and is likely not sterically saturated with DOTA. They tried adding phosphate groups to DOTA to produce DOTP, which seems promising. They are able to calculate the structure and verify with x-ray absorption spectroscopy, particularly EXAFS.


Presented by: Dr. Stosh Kozimor, Los Alamos National Laboratory

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada